Loading clinical trials...

Data Collection in Lutetium Treated Prostate Cancer: Recording of Progression and Tumor Characteristics | Clinical Trials | Clareo Health

RECRUITING

Data Collection in Lutetium Treated Prostate Cancer: Recording of Progression and Tumor Characteristics

NCT06260410•Erasmus Medical Center

View on ClinicalTrials.gov

Summary

This prospective study aims to collect data and blood biomarkers from patients undergoing Lu-PSMA therapy at the Erasmus MC. In doing so, it will provide real-world efficacy and safety data on the drug, gather dosimetry data and explore putative biomarkers to identify patients who most benefit from Lu-PSMA treatment.

Eligibility

Age

18 - No limit years

Sex

MALE

Healthy Volunteers

Inclusion Criteria

•Participants should be at least 18 years old.
•Participants should be able to understand the written information and be able to provide informed consent.
•Participants are planned to start treatment with Lu-PSMA as a part of regular clinical care.

Exclusion Criteria

•None applicable

Locations (1)

Erasmus MC

Rotterdam, South Holland, Netherlands

Key Dates

Start Date

February 20, 2024

Primary Completion Date

February 1, 2027

Completion Date

February 1, 2027

Last Updated

April 22, 2024

Enrollment

150

ESTIMATED participants

Conditions

Prostate Cancer Metastatic

Interventions

Blood draw for ctDNA and circulating tumor cell collection.

DIAGNOSTIC_TEST

Contacts

Stijn Koolen, PhD

CONTACT

+31638740656 s.koolen@erasmusmc.nl

PSMA PET for Surveillance After Focal Therapy

NCT07115914

Prostate Cancer (Adenocarcinoma)Prostate Cancer (Diagnosis)+1 more

View study

RECRUITINGNA

Exercise in Prostate Cancer

NCT06165302

Prostate Cancer MetastaticProstate Cancer

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 22, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Data Collection in Lutetium Treated Prostate Cancer: Recording of Progression and Tumor Characteristics

Inclusion Criteria

Exclusion Criteria

PSMA PET for Surveillance After Focal Therapy

Exercise in Prostate Cancer

Clinical Application of the J-PET Scanner Prototype

Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS)

Androgen Deprivation Therapy (ADT) Versus ADT Plus Prostate Cryotherapy for Metastatic Prostate Cancer (mPCa)

177Lu-HTK03170 in mCRPC With PSMA Positive Disease